Short Physical Performance Battery and Incident Cardiovascular Events Among Older Women.
Short Physical Performance Battery and Incident Cardiovascular Events Among Older Women.
复制标题
DOI:
10.1161/jaha.120.016845
复制
发表时间:
2020-07-21
影响因子:
5.4
通讯作者:
LaCroix AZ
中科院分区:
文献类型:
--
作者:
Bellettiere J;Lamonte MJ;Unkart J;Liles S;Laddu-Patel D;Manson JE;Banack H;Seguin-Fowler R;Chavez P;Tinker LF;Wallace RB;LaCroix AZ
The Short Physical Performance Battery (SPPB) is an inexpensive, reliable, and easy‐to‐implement measure of lower‐extremity physical function. Strong evidence links SPPB scores with all‐cause mortality, but little is known about its relationship with incident cardiovascular disease (CVD). Women (n=5043, mean age=79±7) with no history of myocardial infarction or stroke completed 3 timed assessments—standing balance, strength (5 chair stands), and usual gait speed (4 m walk)—yielding an SPPB score from 0 (worst) to 12 (best). Women were followed for CVD events (myocardial infarction, stroke, or CVD death) up to 6 years. Hazard ratios were estimated for women with Very Low (0–3), Low (4–6), Moderate (7–9), and High (10–12) SPPB scores using Cox proportional hazard models adjusted for demographic, behavioral, and health‐related variables including objective measurements of physical activity, blood pressure, lipids, and glucose levels. Restricted cubic splines tested linearity of associations. With 361 CVD cases, crude incidence rates/1000 person‐years were 41.0, 24.3, 16.1, and 8.6 for Very Low, Low, Moderate, and High SPPB categories, respectively. Corresponding fully adjusted hazard ratios (95% CIs) were 2.28 (1.50–3.48), 1.70 (1.23–2.36) 1.49 (1.12–1.98), and 1.00 (referent); P‐trend <0.001. The dose‐response relationship was linear (linear P<0.001; nonlinear P>0.38). Results suggest SPPB may provide a measure of cardiovascular health in older adults beyond that captured by traditional risk factors. Because of its high test‐retest reliability and low administrative burden, the SPPB should be a routine part of office‐based CVD risk assessment.